274 related articles for article (PubMed ID: 24295850)
1. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.
Liu KS; Hung IF; Seto WK; Tong T; Hsu AS; Lam FY; But DY; Wong SY; Leung WK
Gut; 2014 Sep; 63(9):1410-5. PubMed ID: 24295850
[TBL] [Abstract][Full Text] [Related]
2. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
Ozturk O; Doganay L; Colak Y; Yilmaz Enc F; Ulasoglu C; Ozdil K; Tuncer I
Arab J Gastroenterol; 2017 Jun; 18(2):62-67. PubMed ID: 28601610
[TBL] [Abstract][Full Text] [Related]
4. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
[TBL] [Abstract][Full Text] [Related]
6. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
7. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial.
Laine L; Hunt R; El-Zimaity H; Nguyen B; Osato M; Spénard J
Am J Gastroenterol; 2003 Mar; 98(3):562-7. PubMed ID: 12650788
[TBL] [Abstract][Full Text] [Related]
8. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
9. Eradication Efficacy of Modified Dual Therapy Compared with Bismuth-Containing Quadruple Therapy as a First-Line Treatment of Helicobacter pylori.
Yang J; Zhang Y; Fan L; Zhu YJ; Wang TY; Wang XW; Chen DF; Lan CH
Am J Gastroenterol; 2019 Mar; 114(3):437-445. PubMed ID: 30807294
[TBL] [Abstract][Full Text] [Related]
10. New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.
Xie Y; Pan X; Li Y; Wang H; Du Y; Xu J; Wang J; Zeng Z; Chen Y; Zhang G; Wu K; Liu D; Lv N
J Antimicrob Chemother; 2018 Jun; 73(6):1681-1687. PubMed ID: 29596646
[TBL] [Abstract][Full Text] [Related]
11. Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Uygun A; Kadayifci A; Yesilova Z; Safali M; Ilgan S; Karaeren N
Clin Ther; 2008 Mar; 30(3):528-34. PubMed ID: 18405790
[TBL] [Abstract][Full Text] [Related]
12. Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Kadayifci A; Uygun A; Polat Z; Kantarcioğlu M; Kılcıler G; Başer O; Ozcan A; Emer O
Turk J Gastroenterol; 2012 Feb; 23(1):8-13. PubMed ID: 22505373
[TBL] [Abstract][Full Text] [Related]
13. Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
Wang Z; Wu S
Singapore Med J; 2012 Apr; 53(4):273-6. PubMed ID: 22511052
[TBL] [Abstract][Full Text] [Related]
14. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
Fu W; Song Z; Zhou L; Xue Y; Ding Y; Suo B; Tian X; Wang L
Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
[TBL] [Abstract][Full Text] [Related]
15. The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Avidan B; Melzer E; Keller N; Bar-Meir S
Isr Med Assoc J; 2001 Mar; 3(3):163-5. PubMed ID: 11303370
[TBL] [Abstract][Full Text] [Related]
16. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
[TBL] [Abstract][Full Text] [Related]
17. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Gravina AG; Solís-Muñoz P; Bermejo F; Molina-Infante J; Castro-Fernández M; Ortuño J; Lucendo AJ; Herranz M; Modolell I; Del Castillo F; Gómez J; Barrio J; Velayos B; Gómez B; Domínguez JL; Miranda A; Martorano M; Algaba A; Pabón M; Angueira T; Fernández-Salazar L; Federico A; Marín AC; McNicholl AG
Aliment Pharmacol Ther; 2015 Apr; 41(8):768-75. PubMed ID: 25703120
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Kim MS; Kim N; Kim SE; Jo HJ; Shin CM; Park YS; Lee DH
BMC Gastroenterol; 2013 Sep; 13():138. PubMed ID: 24050512
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Boixeda D; Bermejo F; Martín-De-Argila C; López-Sanromán A; Defarges V; Hernández-Ranz F; Milicua JM; García-Plaza A
Aliment Pharmacol Ther; 2002 Aug; 16(8):1457-60. PubMed ID: 12182745
[TBL] [Abstract][Full Text] [Related]
20. Esomeprazole, minocycline, metronidazole and bismuth as first-line and second-line regimens for Helicobacter pylori eradication.
Song ZQ; Zhou LY
J Dig Dis; 2016 Apr; 17(4):260-7. PubMed ID: 26946480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]